{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:19:57Z","timestamp":1788286797984,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005946","name":"Jackson Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.medj.2025.100956","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:15:59Z","timestamp":1767975359000},"page":"100956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trojan horses at leptomeningeal cellular gates: Antibody\u2013drug conjugates deliver cytotoxic payloads"],"prefix":"10.1016","volume":"7","author":[{"given":"Mina","family":"Nikanjam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100956_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.08.001","article-title":"The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis","volume":"6","author":"Vaz Batista","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.medj.2025.100956_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163996","article-title":"Overcoming Resistance to HER2-Directed Therapies in Breast Cancer","volume":"14","author":"Schlam","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2025.100956_bib3","first-page":"243","article-title":"Novel clinical trial designs emerging from the molecular reclassification of cancer","volume":"75","author":"Nikanjam","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.medj.2025.100956_bib4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2025.100956_bib5","unstructured":"Trastuzumab deruxtecan Package Insert. https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Enhertu&inline=true. Accessed October 22, 2025."},{"key":"10.1016\/j.medj.2025.100956_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100956_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.trecan.2025.04.015","article-title":"Ag(e)nostic precision oncology therapy approvals across the years","volume":"11","author":"Kudek","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.medj.2025.100956_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.14694\/EdBook_AM.2013.33.127","article-title":"Molecular profiling and the reclassification of cancer: divide and conquer","volume":"127\u2013134","author":"Munoz","year":"2013","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.medj.2025.100956_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2025.10.004","article-title":"Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies","volume":"117","author":"Nikanjam","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.medj.2025.100956_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104269","article-title":"Why does HER2-positive breast cancer metastasize to the brain and what can we do about it?","volume":"195","author":"Xu","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.medj.2025.100956_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-07191-3","article-title":"Survival outcomes among patients with breast cancer and leptomeningeal disease","volume":"15","author":"Id Said","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2025.100956_bib12","unstructured":"Batool A, Kasi A. Leptomeningeal Carcinomatosis. StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499862\/#:\u223c:text=Prognosis%20remains%20grim%20in%20patients,are%20markers%20of%20poor%20prognosis. Accessed October 22, 2025."},{"key":"10.1016\/j.medj.2025.100956_bib13","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1200\/EDBK_100006","article-title":"Targeted Therapy in Brain Metastases: Ready for Primetime?","volume":"35","author":"Venur","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.medj.2025.100956_bib14","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jtho.2018.03.018","article-title":"Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases","volume":"13","author":"Li","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.medj.2025.100956_bib15","series-title":"Tucatinib-trastuzumab-capecitabine for Treatment of Leptomeningeal Metastasis in HER2+ Breast Cancer: TBCRC049 Phase 2 Study Results","author":"O'Brien","year":"2024"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:04:55Z","timestamp":1773961495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025003836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666634025003836"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100956","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trojan horses at leptomeningeal cellular gates: Antibody\u2013drug conjugates deliver cytotoxic payloads","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100956"}}